Image-guided percutaneous microwave ablation for unresectable pancreatic cancers: A multicenter retrospective study

Abstract

ObjectiveThis study aims to assess the feasibility, effectiveness, and safety of image-guided percutaneous microwave ablation (PMWA) for unresectable pancreatic cancer. MethodsIn this retrospective study, 72 patients from four hospitals were enrolled between November 2009 and October 2022. Descriptive statistics were employed to describe the patients’ characteristics and prognostic factors. The primary endpoint compassed the complete ablation rate (CAR), incidence of complications and the pain relief rate (PRR). ResultsThe median age of the 72 patients was 61 (interquartile range (IQR) 52.5–67.0) years, with 62.5 % (45/72) being male. 26 cases received computed tomography (CT) guidance; 46 cases received ultrasound guidance. A total of 74 tumors were identified (2 in 2 patients), with 56.8 % (42/74) at the body and tail, and the rest at the head and neck. Overall, 73 ablation sessions were carried out, achieving a technical success rate (TSR) of 100 %. The CAR was 40.5 % (30/74). The median follow-up time was 4.6 (1–43.4) months. 50 % (36/72) of patients had died with a median overall survival (OS) of 5.6 (1–27) months. Regarding complications, 18.1 % (13/72) of cases were classified as grade I and II, and 9.8 % (7/72) as grade IIIa. Before surgery, 33 patients experienced pain symptoms, and the postoperative PRR was 96.7 % (32/33). The average pain score decreased from 6.3 (4–10) before surgery to 2.0 (0–8) after ablation (P<0.001). ConclusionsImage-guided PMWA for unresectable pancreatic cancer is safe and feasible, effectively relieving cancer pain and improving patients’ the quality of life.